Hemogenyx Total Operating Expenses vs Net Income Analysis

HEMO Stock

343.40 20.90 6.48%

Hemogenyx Pharmaceuticals financial indicator trend analysis is much more than just examining Hemogenyx Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hemogenyx Pharmaceuticals is a good investment. Please check the relationship between Hemogenyx Pharmaceuticals Total Operating Expenses and its Net Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemogenyx Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Total Operating Expenses vs Net Income

Total Operating Expenses vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hemogenyx Pharmaceuticals Total Operating Expenses account and Net Income. At this time, the significance of the direction appears to have pay attention.

The correlation between Hemogenyx Pharmaceuticals' Total Operating Expenses and Net Income is -0.87. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Net Income in the same time period over historical financial statements of Hemogenyx Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Hemogenyx Pharmaceuticals' Total Operating Expenses and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Hemogenyx Pharmaceuticals PLC are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Total Operating Expenses i.e., Hemogenyx Pharmaceuticals' Total Operating Expenses and Net Income go up and down completely randomly.

Correlation Coefficient

-0.87

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Hemogenyx Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Hemogenyx Pharmaceuticals PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most indicators from Hemogenyx Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hemogenyx Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemogenyx Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to gain to about 5.2 M in 2024. Issuance Of Capital Stock is likely to gain to about 5.3 M in 2024

Hemogenyx Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Current Deferred Revenue	Accounts Payable	Non Current Assets Total	Other Assets	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Short Long Term Debt	Short Term Debt	Intangible Assets	Property Plant And Equipment Net
Total Assets		0.91	-0.38	-0.79	0.85	0.85	0.81	0.84	0.48	0.89	0.88	0.59	0.22	0.47	0.87	0.13	0.95	0.73	0.51	0.58	0.96	0.61	0.01	0.2	0.94	0.68
Total Stockholder Equity	0.91		-0.7	-0.59	0.96	0.96	0.61	0.63	0.37	0.97	0.71	0.21	0.21	0.26	0.75	0.06	0.76	0.47	0.4	0.26	0.87	0.26	-0.08	0.02	0.8	0.41
Net Debt	-0.38	-0.7		-0.14	-0.75	-0.75	-0.15	0.08	0.23	-0.71	-0.03	0.44	-0.16	0.08	-0.07	0.06	-0.13	0.3	0.03	0.47	-0.38	0.47	0.02	0.16	-0.16	0.35
Retained Earnings	-0.79	-0.59	-0.14		-0.5	-0.5	-0.71	-0.98	-0.84	-0.56	-0.97	-0.73	-0.14	-0.53	-0.94	-0.18	-0.85	-0.93	-0.6	-0.83	-0.81	-0.87	-0.04	-0.31	-0.88	-0.91
Cash	0.85	0.96	-0.75	-0.5		1.0	0.65	0.57	0.26	0.99	0.65	0.16	0.26	0.34	0.64	0.04	0.69	0.36	0.32	0.18	0.85	0.22	0.07	0.13	0.68	0.29
Cash And Short Term Investments	0.85	0.96	-0.75	-0.5	1.0		0.65	0.57	0.26	0.99	0.65	0.16	0.26	0.34	0.64	0.04	0.69	0.36	0.32	0.18	0.85	0.22	0.07	0.13	0.68	0.29
Common Stock Total Equity	0.81	0.61	-0.15	-0.71	0.65	0.65		0.77	0.43	0.69	0.81	0.73	0.44	0.66	0.65	0.21	0.77	0.59	0.46	0.55	0.84	0.67	0.27	0.43	0.71	0.53
Common Stock Shares Outstanding	0.84	0.63	0.08	-0.98	0.57	0.57	0.77		0.8	0.63	0.99	0.75	0.17	0.5	0.95	0.21	0.88	0.93	0.63	0.86	0.83	0.89	0.0	0.27	0.89	0.9
Other Current Assets	0.48	0.37	0.23	-0.84	0.26	0.26	0.43	0.8		0.35	0.78	0.44	0.15	0.27	0.79	0.03	0.51	0.74	0.41	0.66	0.47	0.65	-0.09	0.13	0.65	0.72
Total Current Assets	0.89	0.97	-0.71	-0.56	0.99	0.99	0.69	0.63	0.35		0.71	0.21	0.26	0.36	0.7	0.06	0.73	0.41	0.37	0.23	0.88	0.27	0.06	0.14	0.74	0.34
Common Stock	0.88	0.71	-0.03	-0.97	0.65	0.65	0.81	0.99	0.78	0.71		0.7	0.23	0.5	0.96	0.2	0.88	0.89	0.62	0.8	0.88	0.83	0.0	0.25	0.9	0.85
Short Long Term Debt Total	0.59	0.21	0.44	-0.73	0.16	0.16	0.73	0.75	0.44	0.21	0.7		0.25	0.6	0.62	0.18	0.73	0.81	0.43	0.83	0.57	0.91	0.15	0.4	0.65	0.8
Other Current Liab	0.22	0.21	-0.16	-0.14	0.26	0.26	0.44	0.17	0.15	0.26	0.23	0.25		0.13	0.16	-0.41	0.04	0.1	-0.31	0.04	0.22	0.07	-0.04	-0.02	0.15	0.05
Total Current Liabilities	0.47	0.26	0.08	-0.53	0.34	0.34	0.66	0.5	0.27	0.36	0.5	0.6	0.13		0.37	0.11	0.5	0.42	0.24	0.27	0.55	0.57	0.84	0.95	0.35	0.37
Net Tangible Assets	0.87	0.75	-0.07	-0.94	0.64	0.64	0.65	0.95	0.79	0.7	0.96	0.62	0.16	0.37		0.16	0.87	0.91	0.61	0.78	0.83	0.76	-0.14	0.12	0.93	0.89
Current Deferred Revenue	0.13	0.06	0.06	-0.18	0.04	0.04	0.21	0.21	0.03	0.06	0.2	0.18	-0.41	0.11	0.16		0.17	0.13	0.88	0.18	0.2	0.21	0.05	0.09	0.05	0.14
Accounts Payable	0.95	0.76	-0.13	-0.85	0.69	0.69	0.77	0.88	0.51	0.73	0.88	0.73	0.04	0.5	0.87	0.17		0.84	0.56	0.74	0.9	0.76	0.02	0.25	0.96	0.8
Non Current Assets Total	0.73	0.47	0.3	-0.93	0.36	0.36	0.59	0.93	0.74	0.41	0.89	0.81	0.1	0.42	0.91	0.13	0.84		0.55	0.93	0.68	0.93	-0.09	0.2	0.85	1.0
Other Assets	0.51	0.4	0.03	-0.6	0.32	0.32	0.46	0.63	0.41	0.37	0.62	0.43	-0.31	0.24	0.61	0.88	0.56	0.55		0.53	0.55	0.54	-0.04	0.12	0.49	0.55
Non Current Liabilities Total	0.58	0.26	0.47	-0.83	0.18	0.18	0.55	0.86	0.66	0.23	0.8	0.83	0.04	0.27	0.78	0.18	0.74	0.93	0.53		0.52	0.94	-0.23	0.07	0.73	0.94
Other Stockholder Equity	0.96	0.87	-0.38	-0.81	0.85	0.85	0.84	0.83	0.47	0.88	0.88	0.57	0.22	0.55	0.83	0.2	0.9	0.68	0.55	0.52		0.59	0.12	0.29	0.88	0.63
Total Liab	0.61	0.26	0.47	-0.87	0.22	0.22	0.67	0.89	0.65	0.27	0.83	0.91	0.07	0.57	0.76	0.21	0.76	0.93	0.54	0.94	0.59		0.11	0.4	0.7	0.92
Short Long Term Debt	0.01	-0.08	0.02	-0.04	0.07	0.07	0.27	0.0	-0.09	0.06	0.0	0.15	-0.04	0.84	-0.14	0.05	0.02	-0.09	-0.04	-0.23	0.12	0.11		0.95	-0.15	-0.14
Short Term Debt	0.2	0.02	0.16	-0.31	0.13	0.13	0.43	0.27	0.13	0.14	0.25	0.4	-0.02	0.95	0.12	0.09	0.25	0.2	0.12	0.07	0.29	0.4	0.95		0.08	0.16
Intangible Assets	0.94	0.8	-0.16	-0.88	0.68	0.68	0.71	0.89	0.65	0.74	0.9	0.65	0.15	0.35	0.93	0.05	0.96	0.85	0.49	0.73	0.88	0.7	-0.15	0.08		0.82
Property Plant And Equipment Net	0.68	0.41	0.35	-0.91	0.29	0.29	0.53	0.9	0.72	0.34	0.85	0.8	0.05	0.37	0.89	0.14	0.8	1.0	0.55	0.94	0.63	0.92	-0.14	0.16	0.82

Click cells to compare fundamentals

Hemogenyx Pharmaceuticals Account Relationship Matchups

Hemogenyx Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.0M	2.7M	8.5M	7.1M	6.1M	3.5M
Total Stockholder Equity	(346.5K)	890.8K	8.2M	3.3M	2.8M	2.1M
Net Debt	758.6K	(184.2K)	(6.8M)	890.1K	1.7M	1.8M
Retained Earnings	(6.0M)	(8.0M)	(13.1M)	(17.1M)	(23.8M)	(22.6M)
Cash	498.7K	1.8M	6.8M	2.5M	1.2M	1.9M
Cash And Short Term Investments	498.7K	1.8M	6.8M	2.5M	1.2M	1.9M
Common Stock Total Equity	3.6M	3.6M	3.6M	4.3M	5.0M	2.9M
Common Stock Shares Outstanding	360.7M	414.8M	774.0M	979.7M	1.1B	1.2B
Liabilities And Stockholders Equity	1.0M	2.7M	8.5M	7.1M	6.1M	3.5M
Other Current Assets	55.8K	105.0K	298.2K	62.0K	922.0K	968.1K
Total Current Assets	554.5K	1.9M	7.1M	2.6M	2.2M	2.1M
Common Stock	3.6M	3.6M	4.3M	9.8M	11.8M	12.3M
Short Long Term Debt Total	1.3M	1.6M	10.2K	3.4M	2.9M	1.5M
Other Current Liab	80.3K	47.5K	46.9K	51.9K	77.3K	71.2K
Total Current Liabilities	181.6K	1.8M	352.8K	748.4K	652.1K	526.2K
Net Tangible Assets	686.4K	(608.6K)	635.9K	7.8M	8.9M	9.4M
Accounts Payable	61.4K	113.2K	295.8K	374.3K	301.7K	154.9K
Non Current Assets Total	495.4K	747.3K	1.4M	4.5M	3.9M	4.1M
Non Current Liabilities Total	1.2M	10.0K	306.0K	3.1M	2.7M	2.8M
Other Stockholder Equity	7.7M	10.0M	23.0M	16.8M	14.9M	10.1M
Total Liab	1.4M	1.8M	352.8K	3.8M	3.3M	3.5M
Accumulated Other Comprehensive Income	452.5K	756.9K	878.3K	(58.8K)	1.1M	1.1M
Intangible Assets	272.8K	262.1K	255.0K	441.5K	470.2K	356.6K
Property Plant And Equipment Net	233.4K	268.7K	797.1K	3.9M	3.3M	3.5M
Non Currrent Assets Other	0.0	223.6K	142.6K	140.8K	153.7K	155.6K
Net Receivables	32.3K	56.3K	7.5K	9.8K	5.1K	4.9K
Property Plant Equipment	173.9K	233.4K	268.7K	797.1K	916.7K	962.5K
Net Invested Capital	797.6K	2.5M	8.2M	3.3M	2.8M	3.4M
Property Plant And Equipment Gross	233.4K	268.7K	1.1M	4.5M	4.0M	4.2M
Net Working Capital	372.9K	138.4K	6.8M	1.8M	1.5M	2.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Hemogenyx Stock Analysis

When running Hemogenyx Pharmaceuticals' price analysis, check to measure Hemogenyx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemogenyx Pharmaceuticals is operating at the current time. Most of Hemogenyx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hemogenyx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemogenyx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hemogenyx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Hemogenyx Total Operating Expenses vs Net Income Analysis

Total Operating Expenses vs Net Income

Total Operating Expenses vs Net Income Correlation Analysis

Correlation Coefficient

Total Operating Expenses

Net Income

Hemogenyx Pharmaceuticals fundamental ratios Correlations

Hemogenyx Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Hemogenyx Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Hemogenyx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Net	+ 1.0	Non Current Assets Total
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Common Stock	+ 0.99	Common Stock Shares Outstanding
Total Current Assets	+ 0.97	Total Stockholder Equity

Common Stock Shares Outstanding	- 0.98	Retained Earnings
Common Stock	- 0.97	Retained Earnings
Net Tangible Assets	- 0.94	Retained Earnings
Non Current Assets Total	- 0.93	Retained Earnings
Property Plant And Equipment Net	- 0.91	Retained Earnings
Intangible Assets	- 0.88	Retained Earnings